ADCT (STOCKS)
ADC Therapeutics SA
$1.060000
+0.010000 (+0.95%)
Prev close: $1.050000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Pharmaceuticals Major
- CEO
- Ameet Mallik, MBA
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $134.80M
- Employees
- 263
- P/E (TTM)
- -1.00
- P/B (TTM)
- -0.62
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.13 | $-0.22 | +0.0893 | +40.72% |
|
Dec 2025 (Q4)
|
$-0.04 | $-0.27 | +0.2337 | +85.39% |
|
Sep 2025 (Q3)
|
$-0.30 | $-0.37 | +0.0689 | +18.68% |
|
Jun 2025 (Q2)
|
$-0.38 | $-0.48 | +0.1035 | +21.41% |
Financial Statements
| Revenues | $79.18M |
| Benefits Costs and Expenses | $215.31M |
| Costs And Expenses | $197.46M |
| Nonoperating Income/Loss | -$17.86M |
| Operating Expenses | $191.66M |
| Research and Development | $94.95M |
| Other Operating Expenses | $96.70M |
| Operating Income/Loss | -$118.28M |
| Income/Loss From Continuing Operations After Tax | -$136.99M |
| Income/Loss From Continuing Operations Before Tax | -$136.14M |
| Income Tax Expense/Benefit | $850.00K |
| Net Income/Loss | -$136.99M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$136.99M |
| Net Income/Loss Available To Common Stockholders, Basic | -$136.99M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.99 |
| Diluted Earnings Per Share | -$0.99 |
| Basic Average Shares | 412,161,902 |
| Diluted Average Shares | 412,161,902 |
| Assets | $291.50M |
| Current Assets | $276.77M |
| Inventory | $4.78M |
| Other Current Assets | $271.99M |
| Noncurrent Assets | $14.73M |
| Liabilities | $507.87M |
| Current Liabilities | $67.63M |
| Accounts Payable | $5.30M |
| Other Current Liabilities | $62.33M |
| Noncurrent Liabilities | $440.25M |
| Equity | -$216.38M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$216.38M |
| Liabilities And Equity | $291.50M |
| Net Cash Flow From Operating Activities | -$114.55M |
| Net Cash Flow From Operating Activities, Continuing | -$114.55M |
| Net Cash Flow From Investing Activities | $627.00K |
| Net Cash Flow From Investing Activities, Continuing | $627.00K |
| Net Cash Flow From Financing Activities | $150.09M |
| Net Cash Flow From Financing Activities, Continuing | $150.09M |
| Exchange Gains/Losses | $139.00K |
| Net Cash Flow | $36.31M |
| Net Cash Flow, Continuing | $36.17M |
| Comprehensive Income/Loss | -$136.70M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$136.70M |
| Other Comprehensive Income/Loss | -$136.70M |
| Other Comprehensive Income/Loss Attributable To Parent | $290.00K |